Snoring can be frustrating and annoying, especially for those who sleep with a snorer. The National Sleep Foundation reports that one in three men and four women snore every night.
Though snoring is often overlooked as a minor issue, it can occur due to various reasons requiring immediate attention. Obesity or being overweight is one of the leading causes of snoring. Snoring accompanied by irregular breathing is a sign of cardiovascular disease risk. Sleep apnoea can be another condition that increases the chances of snoring. Sleep apnoea is a sleep disorder in which the breathing repeatedly stops and resumes again. Fortunately, plenty of remedies are available to treat snoring naturally without using over-the-counter (OTC) drugs.
Obesity or Excess Weight
For those who have started snoring after gaining weight, shedding some extra pounds can be quite helpful. Obese people tend to have excess tissue and fat in the neck region, which can reduce the airway size and elevate the risk of airway collapse. Studies have proved that weight reduction can eliminate the frequency of snoring with increased weight losses causing near to complete elimination of snoring.
Snoring accelerates when people lie in the supine position or on their backs. When someone lies down on the back, the tissues surrounding the airway are pulled down by gravity, making it narrow. Research and studies on snorers have revealed that the intensity and frequency of snoring reduce considerably when they lie on their sides.
Blocked Nasal Passages
Snoring can also be prevented by keeping the nasal passages open. When the nose is clogged or blocked, air moves in much faster, leading to snoring. Hot oil massages or nasal oil drops can open the blockages in the nose. Also, a hot shower before bed can be quite beneficial as the moisture opens the nasal passages and reduces the chances of snoring.
Staying hydrated is crucial not only to avoid snoring but also to maintain overall health and well-being. When the body is dehydrated, secretions in the nose and soft palate becomes stickier. This can obstruct the proper flow of air and cause snoring. For men, it is recommended to consume at least 3-4 litres of fluid every day, while women must consume 2-3 litres of fluids daily.
Smoking and Alcohol
Researchers believe that snoring in smokers can occur because of oedema and upper airway inflammation. While it takes time to show the effects but quitting smoking can significantly lessen the chances of snoring. Alcohol is another substance that relaxes the muscles around the airway, increasing the likelihood to snore among drinkers. Therefore, it is often recommended not to indulge in drinking in the hours leading to bedtime.
The tips mentioned above can bring positive results if tried daily. It is important to try them all to find the ideal remedy that helps.
Read More► Here's How to Optimise Stress, Sleep and Immunity
Chennai, Aug 2 (IANS) Pharma major Glenmark Pharmaceuticals Ltd on Monday said it has signed a long term partnership with Canandian company SaNOtize Research & Development Corp., to manufacture, market and distribute Nitric Oxide Nasal Spray (NONS) for Covid-19 treatment.According to Glenmark, NONS will be sold in India and in Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam."In March 2021, SaNOtize's clinical trials showed NONS was a safe and effective antiviral treatment to prevent the transmission of Covid-19, shorten its course, and reduce the severity of symptoms," Glenmark said.In the first 24 hours, NONS reduced the average viral load by around 95 per cent, and then by more than 99 per cent within 72 hours. It has been tested in healthy volunteers and patients as part of UK and Canada clinical trials, the Indian company said.The nasal spray, is designed to kill the coronavirus in the upper airways, preventing it from incubating and spreading to the lungs.Glenmark said in India, the phase III clinical trial for NONs is expected to be completed followed by commercial launch under the brand name FabiSpray, by fourth quarter of the calendar year 2021.--IANSvj/in
Chennai, May 3 (IANS) Pharma major Glenmark Pharmaceuticals Limited on Monday announced the launch of Ryaltris-AZ nasal spray for the treatment of moderate to severe allergic rhinitis, in India.Glenmark has been the first to launch the branded generic version for the treatment of allergic rhinitis in India.According to a study, around 20-30 per cent of the Indian population suffers from allergic rhinitis, Glenmark said.Glenmark has priced the nasal spray Ryaltris-AZ at Rs 175 per pack of 75 metered doses (MD). The average cost of therapy of top 10 existing brands of the similar drug category is Rs 365, the company said.According to Glenmark, it is the first company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg.Developed by Glenmark, Ryaltris-AZ is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age.It relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes, Glenmark said.--IANSvj/skp/
Chennai, April 26 (IANS) Pharma major Glenmark Pharmaceuticals Ltd on Monday said it is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray Ryaltris across the European Union.The company said Ryaltris (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg), will shortly be available in Austria, Belgium, the Czech Republic, Germany, Denmark, Spain, Finland, France, Ireland, Italy, The Netherlands, Norway, Poland, Romania, Slovakia, Sweden, as well as the UK.Glenmark will commercialise Ryaltris on its own in select markets.In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark in 2020.Under the terms of the agreement, Glenmark is responsible for the continued development and regulatory approval of Ryaltris in these markets, while Menarini will lead the scientific information and commercialisation of the nasal spray, following regulatory approval.Ryaltris, developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age.It relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.According to Achin Gupta, Executive Vice President, Business Head EMEA-L (Europe, Middle East, Africa, Latam) upwards of 25 per cent of the population in Europe suffers from the debilitating symptoms of allergic rhinitis.Glenmark has also partnered with Hikma Pharmaceuticals PLC and Bausch Health for the commercialisation of Ryaltris in the US and Canada respectively.--IANSvj/vd
San Francisco, March 18 (IANS) Google blocked over 99 million Covid-related ads in 2020, including those for miracle cures, N95 masks due to supply shortages fake vaccine doses.As claims and conspiracies about the coronavirus's origin and spread were circulated online, Google launched a new policy to prohibit both ads and monetised content about Covid-19 or other global health emergencies that contradict scientific consensus. "We continue to be nimble, tracking bad actors' behavior and learning from it. In doing so, we're able to better prepare for future scams and claims that may arise," the company said in a statement on Wednesday. The number of ad accounts Google disabled for policy violations increased by 70 per cent from 1 million to over 1.7 million. The company also blocked or removed over 867 million ads for attempting to evade its detection systems, including cloaking, and an additional 101 million ads for violating its misrepresentation policies."We also continued to invest in our automated detection technology to effectively scan the web for publisher policy compliance at scale," said the company. Due to this investment, along with several new policies, Google removed ads from 1.3 billion publisher pages in 2020, up from 21 million in 2019. It also stopped ads from serving on over 1.6 million publisher sites with pervasive or egregious violations.Over the past few years, we introduced strict policies and restrictions around who can run election-related advertising on Google platform and the ways they can target ads."Globally, we continue to expand our verification programme and verified more than 5,400 additional election advertisers in 2020," Google said. In the US, Google temporarily paused more than five million ads and blocked ads on over three billion Search queries referencing the election, the candidates or its outcome.--IANSna/
<br>Days after getting the Drugs Controller General of India's nod for restricted emergency use of India's first indigenously-made coronavirus vaccine, Bharat Biotech had applied to the drug regulator for permission to start the clinical trials of their nasal coronavirus vaccine.The nasal vaccine is different from the intramuscular vaccine which recently got approval, as it is non-invasive, needle-free, doesn't require trained healthcare workers, eliminates needle-associated risks, suits children and adults and has scalable manufacturing.Earlier on Tuesday, Dr VK Paul, Member, NITI (National Institution for Transforming India) Aayog had said, "A nasal vaccine candidate has been identified. It has come for consideration for phase 1 and phase 2 trials. If it works then it could be a game-changer.""Phase 1 has been recommended," top government sources told IANS. Clinical trials of Bharat Biotech's 'BBV154' -- a novel adenovirus vectored, and intranasal vaccine for coronavirus -- will be conducted at various locations. The vaccine will be single-dosed.According to the firm, an intranasal vaccine stimulates a broad immune response at the site of infection, in the nasal mucosa, which is essential for blocking both infection and transmission of Covid-19.The vaccine has demonstrated protective efficacy in mice and hamsters. Mice and hamsters immunized with its single-dose conferred superior protection against the SARS-CoV-2 challenge, "more so than one or two intramuscular immunizations of the same vaccine and dose.""Thus, intranasal immunization of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus, thereby protecting against disease, infection and transmission," Bharat Biotech said in a statement.On January 3, two intramuscular vaccines - Bharat Biotech's Covaxin and Oxford-AstraZeneca's Covishield manufactured by the Serum Institute of India were approved for restricted emergency use and have been administered to over four lakh people till now. Both are two-dose vaccines.While the full efficacy of Covaxin is yet to be determined, it was given the go-ahead by the DCGI citing 'public interest'. Covaxin is an indigenously developed vaccine by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR).Public health experts believe that intranasal vaccines for coronavirus, administered through the nose rather than muscles, can be a potential game-changer in India's fight against the coronavirus pandemic.Last month, Pune-based Serum Institute of India and Codagenix Inc had announced that they have received regulatory approval in the United Kingdom to begin an early-stage trial of their single-dose, intranasal coronavirus vaccine.(Aakanksha Khajuria can be contacted at [email protected])--IANS<br>aka/bg